Role of fosfomycin tromethamine in modulating non-specific defence mechanisms in chronic uremic patients towards ESBL-producing Escherichia coli

International Journal of Immunopathology and Pharmacology

Volumn 21, Issue 1, 2008, Pages 153-160

  Tullio, Vivian ^a   Cuffini, A M ^a   Banche, G ^a   Mandras, N ^a   Allizond, V ^a   Roana, J ^a   Giacchino, F ^b   Bonello, F ^b   Ungheri, D ^c   Carlone, N A ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Civil Hospital   (Italy)

^c Zambon Group SpA   (Italy)

Author keywords

ESBL producing Escherichia coli; Fosfomycin tromethamine; Intracellular killing; Phagocytosis; PMNs

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN TROMETAMOL;

ADULT; AGED; ANTIMICROBIAL ACTIVITY; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ESCHERICHIA COLI; FEMALE; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; IN VITRO STUDY; KIDNEY TRANSPLANTATION; MALE; PATHOGENESIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; UREMIA; URINARY TRACT INFECTION;

EID: 41849140835     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200802100117     Document Type: Article

References (25)

1. Labro M.T. 2000. Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin. Microbiol. Rev. 13: 615.
2. Morikawa K., M. Nonaka, I. Torii and S. Morikawa. 2003. Modulatory effect of fosfomycin on acute inflammation in the rat air pouch model. Int. J. Antimicrob. Agents 21:334.
3. Periti P. and M. Rizzo. 2000. Ruolo degli antibiotici orali in urologia diagnostica e terapeutica: la fosfomicina trometamolo. Far. Ter. 17:3.
4. Schito G.C. 2003. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int. J. Antimicrob. Agents 22:79.
5. De Cueto M., L. Lopez, J.R. Hernandez, C. Morillo and A. Pascual. 2006. In vitro activity of fosfomycin against extended-spectrum-beta- lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob. Agents Chemother. 50:368.
6. Mazzei T., M.I. Cassetta, S. Fallani, S. Arrigucci and A. Novelli. 2006. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int. J. Antimicrob. Agents 28:S35.
7. Pullukcu H., M. Tasbakan, O.R. Sipahi, T. Yamazhan, S. Aydemir and S. Ulusoy. 2007. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int. J. Antimicrob. Agents 29:62.
8. Marchese A., L. Gualco, E.A. Debbia, G.C Schito and A.M. Schito. 2003. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int. J. Antimicrob. Agents 22:53.
9. Cuffini A.M., V. Tullio, F. Giacchino, A. Bonino, N. Mandras, N. Bianchi, J. Roana, D. Scalas, F. Bonello and N.A. Carlone. 2001. Improved phagocyte response by co-amoxiclav in renal transplant recipients. Transplantation 71:575.
10. Cuffini A.M., V. Tullio, A. Bonino, A. Allocco, A. Ianni Palarchio and N.A. Carlone. 1998. Entry of sanfetrinem into human polymorphonuclear granulocytes and its cell-associated activity against intracellular, penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42: 1745.
11. Tullio V., A.M. Cuffini, A. Bonino, A. Ianni Palarchio, J. Roana, N. Mandras, V. Rossi and N.A. Carlone. 2000. Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with pefloxacin. J. Antimicrob. Chemother. 6:241.
12. Tullio V., A.M. Cuffini, A. Bonino, F. Giacchino, C. Merlino, G.M. Bosticardo, G. Paizis and N.A. Carlone. 1998. Cefonicid "restores" the depressed activities of polymorphonuclear cells from chronic haemodialysis patients and renal transplant recipients in vitro. Nephrol. Dial. Transplant. 13:2017.
13. Banche G., V. Allizond, F. Giacchino, N. Mandras, J. Roana, F. Bonello, P. Belardi, V. Tullio, C. Merlino, N. Carlone and A.M. Cuffini. 2006. Effect of dialysis membrane biocompatibility on polymorphonuclear granulocyte activity in dialysis patients. Nephrol. Dial. Transplant. 21:3532.
14. Horii T., T. Kimura, T. Odagiri, K. Shibayama and M. Ohta. 2000. Medium compositions and culture conditions for the assay of fosfomycin susceptibility by E-test. J. Infect. Chemother. 6:30.
15. th informational supplement. Approved standard M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.
16. Nielsen S.L. and F.T. Black. 1998. The effect of dicloxacillin and fusidic acid on the extracellular and intracellular killing of Staphylococcus aureus. J. Antimicrob. Chemother. 42:221.
17. Tullio V., A. Cuffini, N. Mandras, J. Roana, G. Banche, D. Ungheri and N. Carlone. 2004. Influence of thiamphenicol on the primary functions of human polymorphonuclear leucocytes against Streptococcus pyogenes. Int. J. Antimicrob. Agents 24:381.
18. Cuffini A.M., V. Tullio, N. Mandras, J. Roana, D. Scalas, G. Banche and N.A. Carlone. 2002. Clarithromycin mediated the expression of polymorphonuclear granulocyte response against Streptococcus pneumoniae strains with different patterns of susceptibility and resistance to penicillin and clarithromycin. Int. J. Tissue React. 24:37.
19. Tullio V., A.M. Cuffini, F. Giacchino, N. Mandras, J. Roana, L. Comune, C. Merlino and N.A. Carlone. 2003. Combined action of fluconazole and PMNs from uremic patients in clearing intracellular Candida albicans. J. Chemother. 15:301.
20. Anding K., P. Gross, J.M. Rost, D. Allgaier and E. Jacobs. 2003. The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol. Dial. Transplant. 18: 2067.
21. Mahajan S., O.P. Kalra, K.T. Asit, G. Ahuja and V. Kalra. 2005. Phagocytic polymorphonuclear function in patients with progressive uremia and the effect of acute hemodialysis. Ren. Fail. 27:357.
22. Amurrio C., R. Nicolas, L. Larrauri, A. Lopez and R. Cisterna. 1989. Effect of erythromycin and fosfomycin on the ingestion and destruction capacity of the human polymorphonuclear leukocyte. Enferm. Infecc. Microbiol. Clin. 7:374.
23. Krause R., S. Patruta, F. Daxböck, P. Fladerer and C. Wenisch. 2001. The effect of fosfomycin on neutrophil function. J. Antimicrob. Chemother. 47:141.
24. Mandell G.L. 2005. Uptake, transport, delivery, and intracellular activity of antimicrobial agents. Pharmacotherapy 25:130S.
25. Barry A.L. and P.C. Fuchs. 1991. In vitro susceptibility testing procedures for fosfomycin tromethamine. Antimicrob. Agents Chemother. 35:1235.